Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 11, 2012, Pages 1227-1231

  Purhonen, Maija ^a   Koponen, Hannu ^a,b   Tiihonen, Jari ^b,c,d   Tanskanen, Antti ^c,d  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Drug policy; Market withdrawal; Pharmacoepidemiology; Psychotic relapses; Thioridazine

Indexed keywords

THIORIDAZINE;

ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MARKETING; DRUG WITHDRAWAL; FINLAND; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DRUG UTILIZATION REVIEW; FINLAND; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PRODUCT RECALLS AND WITHDRAWALS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SCHIZOPHRENIA; THIORIDAZINE; TREATMENT OUTCOME;

EID: 84868213432     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3346     Document Type: Article

References (14)

1. Fletcher GF, Kazamias TM, Wenger NK. Cardiotoxic effects of Melleril: Conduction disturbances and supraventricular arrhythmias. Am Heart J 1969; 78: 135-138.
2. Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048-1052.
3. Reilly JG, Ayis SA, Ferrier IN, et al. Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2002; 180: 515-522.
4. Glassmann AH and Bigger JT. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-1782.
5. Stöllberger C, Huber JO and Finsterer J. Antipsychotic drugs and QT prolongation. Int Clinl Psychopharmacol 2005; 20: 243-251.
6. Davies SJC, Cooke LB, Moore AG, et al. Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs. BMJ 2002; 324: 1519-1521
7. Álvarez IB, Paredero JP, Idini E, et al. Repercussions of the withdrawal of thioridazine. Actas Esp Psiquiatr 2008; 36: 183-186.
8. Salokangas RKR. Psychiatric specialist care in Finland-achievements and challenges. J Ment Health 2004; 13: 47-54.
9. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a polulation-based cohort study (FIN11 study). Lancet 2009; 374: 620-627.
10. Bech P, Peuskens JCJR, Marder SR, et al. A. Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics. Eur Psychiatry 1998; 13: 310-314.
11. Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999; 156: 79-87.
12. Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetuapine ('seroquel')and haloperidol in schizophrenic patients with history of and demonstrated, partial response to conventional antipsychotic treatment, PRIZE study group. Int Clin Psychopharmacol 2000; 15: 121-131.
13. Nasrallah HA and Mulvihill T. Iatrogenic disorders associated with conventional vs. atypical antipsychotics. Ann Clin Psychiatry 2001; 13: 215-227.
14. Lorca PM. Partial compliance in schizophrenia and the impact on patients outcomes. Psychiatry Res 2008; 2: 235-247.